Swiss National Bank Ventyx Biosciences, Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$29.8 - $40.3 $232,440 - $314,340	7,800 Added 9.47%	90,200 $3.13 Million
Q2 2023 Aug 09, 2023	BUY	$28.53 - $39.55 $1.3 Million - $1.81 Million	45,700 Added 124.52%	82,400 $2.7 Million
Q1 2023 May 10, 2023	SELL	$29.51 - $46.65 $123,942 - $195,930	-4,200 Reduced 10.27%	36,700 $1.23 Million
Q4 2022 Feb 08, 2023	BUY	$24.16 - $36.38 $988,144 - $1.49 Million	40,900 New	40,900 $1.34 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.